StockData

Clene vs Gelteq

CLNN and GELS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CLNN and GELS compare

Clene scores higher on the StockData Score (1 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCLNNGELS
Size and price
Market cap$41.4M–
Share price$3.22$0.269
Change, 1 year−62.2%−73.0%
Change, 5 years−96.6%–
Beta (5Y)2.241.35
Employees79–
StockData Score
Total score1 (better)0
Valuation score00
Growth score00
Performance score00
Health score1 (better)0
Dividend score00
Valuation
P/S210×–
Growth
Revenue growth (TTM)−31.1%–
Revenue growth, 5Y average−0.59%–
Profitability
Gross margin70.1% (better)30.3%
Operating margin−10432%−3318% (better)
Net margin−20060%–
FCF margin–−3335%
Financial health
Interest coverage−7.1×−2.8× (better)
Current ratio3.07 (better)0.09
Altman Z-score−21.93–
Piotroski F-score2–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions24.8%–
Held by insiders45.9%14.0%
Insider net buying, 12 months−$5.6M–
Short interest, % of float6.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.